Improving Platelet Transfusions for Extremely Preterm Babies
1/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)
This research aims to find the best platelet transfusion levels for extremely premature babies to help prevent serious bleeding.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11088258 on NIH RePORTER |
What this research studies
Extremely preterm babies, especially those born between 23 and 26 weeks, often face severe bleeding, particularly in the brain, which can be very dangerous. Doctors frequently give these tiny infants platelet transfusions, but there's still uncertainty about the ideal platelet count to aim for. This project will help us understand if a lower platelet transfusion level might be safer and more effective for these vulnerable newborns. We hope to reduce the risk of death and serious bleeding by finding the right balance.
Who could benefit from this research
Good fit: Ideal candidates are extremely preterm infants born between 23 and 26 weeks gestation who are admitted to the Neonatal Intensive Care Unit.
Not a fit: Patients who are not extremely preterm infants or who do not require platelet transfusions would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective platelet transfusion guidelines, potentially reducing severe bleeding and improving outcomes for extremely preterm infants.
How similar studies have performed: Previous multicenter trials have explored different platelet transfusion thresholds, but questions remain, especially for the most immature preterm infants in their first week of life.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Patel, Ravi Mangal — Emory University
- Study coordinator: Patel, Ravi Mangal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.